Cargando…

Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations

BACKGROUND: New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilczynski, Ophélie, Boisbouvier, Anthony, Radoszycki, Lise, Cotté, François-Emery, Gaudin, Anne-Françoise, Lemasson, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790682/
https://www.ncbi.nlm.nih.gov/pubmed/35014969
http://dx.doi.org/10.2196/25792
_version_ 1784640070439927808
author Wilczynski, Ophélie
Boisbouvier, Anthony
Radoszycki, Lise
Cotté, François-Emery
Gaudin, Anne-Françoise
Lemasson, Hervé
author_facet Wilczynski, Ophélie
Boisbouvier, Anthony
Radoszycki, Lise
Cotté, François-Emery
Gaudin, Anne-Françoise
Lemasson, Hervé
author_sort Wilczynski, Ophélie
collection PubMed
description BACKGROUND: New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poorly documented. OBJECTIVE: This study describes experiences and expectations of patients treated with ICIs regarding a discussion of HRQoL with health care professionals (HCPs) in cancer management. METHODS: This cross-sectional study was conducted in an online patient community (Carenity) in France. Patients treated with ICIs for cancer, included between September 2018 and January 2019, completed a questionnaire to assess the involvement of HCP in a discussion of HRQoL and when and what was discussed. RESULTS: Of 82 patients included (mean age: 56.9 years, 95% CI 54.2-59.6; 46 [56%] male; 34 [41%] with lung cancer), 62 (76%) reported discussing HRQoL at least once with HCPs, mainly general practitioners (54/82, 66%), oncologists (53/82, 65%), and hospital nurses (50/82, 61%). Around half (45/82, 55%) of the patients were satisfied with these discussions. Discussions with the oncologist were at the patient’s initiative (34/53, 64%). Discussions occurred primarily during follow-up visits (40/62, 65%), when adverse events occurred (30/62, 48%), and at treatment initiation (27/62, 32%). The most discussed dimensions were symptoms (48/62, 77%) and physical well-being (43/62, 69%). With respect to expectations, 54/82 (66%) patients considered oncologists as the most important HCPs for discussing HRQoL. These discussions were desirable throughout the care pathway, particularly at diagnosis (63/82, 77%) and when treatment was initiated (75/82, 92%) or changed (68/82, 83%). All HRQoL dimensions were considered important to discuss. CONCLUSIONS: With only around half of the patients satisfied with HRQoL discussions, impactful HRQoL integration in clinical practice is critical. According to patients, this integration should involve mainly oncologists and general practitioners, should happen at every step of the care pathway, and should be extended to dimensions that are currently rarely addressed.
format Online
Article
Text
id pubmed-8790682
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-87906822022-02-03 Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations Wilczynski, Ophélie Boisbouvier, Anthony Radoszycki, Lise Cotté, François-Emery Gaudin, Anne-Françoise Lemasson, Hervé J Med Internet Res Original Paper BACKGROUND: New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poorly documented. OBJECTIVE: This study describes experiences and expectations of patients treated with ICIs regarding a discussion of HRQoL with health care professionals (HCPs) in cancer management. METHODS: This cross-sectional study was conducted in an online patient community (Carenity) in France. Patients treated with ICIs for cancer, included between September 2018 and January 2019, completed a questionnaire to assess the involvement of HCP in a discussion of HRQoL and when and what was discussed. RESULTS: Of 82 patients included (mean age: 56.9 years, 95% CI 54.2-59.6; 46 [56%] male; 34 [41%] with lung cancer), 62 (76%) reported discussing HRQoL at least once with HCPs, mainly general practitioners (54/82, 66%), oncologists (53/82, 65%), and hospital nurses (50/82, 61%). Around half (45/82, 55%) of the patients were satisfied with these discussions. Discussions with the oncologist were at the patient’s initiative (34/53, 64%). Discussions occurred primarily during follow-up visits (40/62, 65%), when adverse events occurred (30/62, 48%), and at treatment initiation (27/62, 32%). The most discussed dimensions were symptoms (48/62, 77%) and physical well-being (43/62, 69%). With respect to expectations, 54/82 (66%) patients considered oncologists as the most important HCPs for discussing HRQoL. These discussions were desirable throughout the care pathway, particularly at diagnosis (63/82, 77%) and when treatment was initiated (75/82, 92%) or changed (68/82, 83%). All HRQoL dimensions were considered important to discuss. CONCLUSIONS: With only around half of the patients satisfied with HRQoL discussions, impactful HRQoL integration in clinical practice is critical. According to patients, this integration should involve mainly oncologists and general practitioners, should happen at every step of the care pathway, and should be extended to dimensions that are currently rarely addressed. JMIR Publications 2022-01-11 /pmc/articles/PMC8790682/ /pubmed/35014969 http://dx.doi.org/10.2196/25792 Text en ©Ophélie Wilczynski, Anthony Boisbouvier, Lise Radoszycki, François-Emery Cotté, Anne-Françoise Gaudin, Hervé Lemasson. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 11.01.2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Wilczynski, Ophélie
Boisbouvier, Anthony
Radoszycki, Lise
Cotté, François-Emery
Gaudin, Anne-Françoise
Lemasson, Hervé
Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
title Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
title_full Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
title_fullStr Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
title_full_unstemmed Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
title_short Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
title_sort integrating quality of life in the care pathway of cancer patients undergoing immunotherapy treatment: descriptive, cross-sectional survey of an online patient community's experiences and expectations
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790682/
https://www.ncbi.nlm.nih.gov/pubmed/35014969
http://dx.doi.org/10.2196/25792
work_keys_str_mv AT wilczynskiophelie integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations
AT boisbouvieranthony integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations
AT radoszyckilise integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations
AT cottefrancoisemery integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations
AT gaudinannefrancoise integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations
AT lemassonherve integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations